Gilead Sciences, Inc. $GILD Holdings Cut by WBI Investments LLC

WBI Investments LLC lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 41.5% in the third quarter, HoldingsChannel reports. The institutional investor owned 8,734 shares of the biopharmaceutical company’s stock after selling 6,203 shares during the period. WBI Investments LLC’s holdings in Gilead Sciences were worth $969,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of GILD. Corundum Trust Company INC acquired a new stake in Gilead Sciences during the third quarter valued at $26,000. Howard Hughes Medical Institute acquired a new position in Gilead Sciences in the 2nd quarter worth about $30,000. MTM Investment Management LLC increased its position in Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 176 shares during the last quarter. Kilter Group LLC purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth about $33,000. Finally, Millstone Evans Group LLC raised its stake in shares of Gilead Sciences by 58.7% during the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 118 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, March 16th. The shares were sold at an average price of $144.23, for a total value of $432,690.00. Following the transaction, the insider owned 131,779 shares in the company, valued at $19,006,485.17. This trade represents a 2.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the transaction, the chief executive officer directly owned 642,308 shares of the company’s stock, valued at approximately $92,999,775.32. This represents a 1.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 309,280 shares of company stock valued at $44,068,850 over the last three months. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $144.40 on Wednesday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The firm has a market cap of $179.26 billion, a price-to-earnings ratio of 21.33, a P/E/G ratio of 1.90 and a beta of 0.37. The business’s 50-day simple moving average is $141.62 and its 200-day simple moving average is $127.41. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be paid a $0.82 dividend. The ex-dividend date is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. Gilead Sciences’s dividend payout ratio is presently 48.45%.

Analyst Ratings Changes

Several brokerages recently commented on GILD. Scotiabank boosted their price target on Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a research note on Wednesday, February 11th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. Cantor Fitzgerald lifted their target price on shares of Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $103.00 to $118.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 11th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Twenty-four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $157.62.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.